Trial Profile
A Prospective, Observational study to evaluate the impact of Type-2-Diabetes on direct oral anticoagulants (DOACs) activity in patients non-valvular atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Pharmacodynamics; Pharmacokinetics
- 22 May 2018 New trial record